Your browser doesn't support javascript.
loading
Author's Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613-627.
Young-Xu, Yinong; Melsheimer, Richard; Emond, Bruno; Lefebvre, Patrick; DerSarkissian, Maral; Lax, Angela; Nguyen, Catherine; Bhak, Rachel H; Wu, Melody; Lin, Iris.
Afiliação
  • Young-Xu Y; White River Junction VA Medical Center, White River Junction, VT, USA.
  • Melsheimer R; Janssen Biologics BV, Leiden, the Netherlands.
  • Emond B; Analysis Group, Inc, Montréal, Québec, Canada.
  • Lefebvre P; Analysis Group, Inc, Montréal, Québec, Canada.
  • DerSarkissian M; Analysis Group, Inc, Montréa, Québec, Canada.
  • Lax A; Analysis Group, Inc, Los Angeles, CA, USA.
  • Nguyen C; Analysis Group, Inc, Montréa, Québec, Canada.
  • Bhak RH; Analysis Group, Inc, Los Angeles, CA, USA.
  • Wu M; Analysis Group, Inc, Los Angeles, CA, USA.
  • Lin I; Analysis Group, Inc., Boston, MA, USA.
Curr Med Res Opin ; 38(12): 2237-2240, 2022 12.
Article em En | MEDLINE | ID: mdl-36274636
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veteranos / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veteranos / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article